Acutaas Chemicals Limited has informed the Exchange regarding a press release dated July 30, 2025, titled "Q1 FY 26 Results".
ACUTAAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Acutaas Chemicals (formerly Ami Organics) reported strong Q1 FY26 results with revenue from operations at Rs. 2,072 million, up 17.3% year-on-year. EBITDA surged 72.4% YoY to Rs. 509 million, with margins expanding sharply by 785 basis points to 24.6%. Profit after tax nearly tripled, rising 199.6% YoY to Rs. 440 million, pushing PAT margin to 21.2% from about 8.4% in the same quarter last year. The company highlighted that both pharma facilities are now PMDA GMP certified and announced a new joint venture in South Korea targeting semiconductor markets. Exports contributed 60% of revenue while domestic sales made up the remaining 40%. Management expressed confidence in delivering 25% growth with improved margins for the full year.
This is a strong earnings beat with double-digit revenue growth and significant margin expansion, likely to be viewed positively by the market. The PMDA certification, new South Korea JV, and upbeat guidance signal continued momentum, which could support near-term investor sentiment and stock price.